PET/CT and Molecular Profiling: A New Blueprint for Managing Advanced Lung Cancer
A recent correspondence in the Annals of Oncology critically examines a study on a PET/CT-guided management strategy for metastatic lung cancer patients who have achieved long-term disease control with first-line immune checkpoint blockade (ICB). The original research, part of the National Network Genomic Medicine Lung Cancer Germany (nNGM), proposed using PET/CT imaging to inform decisions on potentially de-escalating or continuing ICB therapy after two years. This new analysis highlights the need for methodological clarity in such de-escalation trials, particularly concerning patient selection, biomarker integration, and the comprehensive molecular profiling of long-term responders to understand the mechanisms behind sustained remission.
Why it might matter to you: This discussion underscores the evolving intersection of diagnostic imaging, molecular diagnostics, and therapeutic decision-making in oncology. For pathologists, it reinforces the critical role of integrated diagnostics—where radiological findings from PET/CT must be correlated with tissue-based analyses, including tumor grading, staging, and biomarker assessment via immunohistochemistry and next-generation sequencing. The push for multi-modal profiling in long-term responders directly impacts your work in providing the essential histopathological and molecular data that guide these precision oncology strategies and define novel biomarkers of treatment success.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
